Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
344
resultados
Última actualización
09/10/2026 [07:36:00]
Resumen de: EP4818331A2
0001 The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.
Resumen de: EP4818330A1
The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein rhereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.
Resumen de: WO2025059015A1
Described herein is a system comprising a eukaryotic cell, wherein the eukaryotic cell comprises: a plasma membrane polypeptide coupled to a transcription factor by a linker, wherein the linker comprises a protease cleavable site; and a plasma membrane anchored protease; wherein the plasma membrane anchored protease is capable of cleaving the linker. The system can further include a reporter construct, wherein the transcription factor can bind to a promoter of the reporter construct to indicate an ability of the plasma membrane polypeptide to traffic to the plasma membrane.
Resumen de: AU2019205489A1
This invention generally pertains to antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, compositions containing such antibodies and antigen-binding fragments thereof and fusion proteins, wherein such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non-human MCT1 and antagonize, inhibit or block one or more MCT1-associated functions
Resumen de: WO2026205616A1
The present invention relates to an anti-APP antibody or an antigen-binding fragment thereof, and uses thereof. Specifically, the anti-APP antibody or antigen-binding fragment thereof according to the present invention may be utilized for analysis and detection of cell membrane APP, and further for diagnosis of APP-related diseases.
Resumen de: WO2026207317A1
A method for screening a subject in need thereof for amyotrophic lateral sclerosis (ALS) or slowing a progression of ALS, wherein the method includes measuring a level of at least a biomarker in the subject, such as without limitation by using a synthetic antibody, determining an ALS status indicator as a function of the measurement, and optionally providing a treatment to slow the progression of ALS as a function of the ALS status indicator, wherein the at least a biomarker includes a trimeric superoxide dismutase 1 (SOD1).
Resumen de: US20260298931A1
0000 A method for detecting colorectal cancer DNA using a lateral flow assay includes: extracting a blood sample (S100); loading the blood sample on a lateral flow assay (LFA) kit (S110); amplifying a specific target circulating tumor DNA (ctDNA) fragment using single nucleotide polymorphism (SNP) typing based on a loop-mediated isothermal amplification (LAMP) device on the kit (S130); allowing the amplified SNP sequence to move along a nitrocellulose membrane and binding to a gold nanoparticle probe to form a DNA-AuNP complex (S140); and color-developing a first probe to be visually detected in the complex forming process (S150), so as to detect whether colorectal cancer mutant DNA exists in the blood sample based on the color development.
Resumen de: WO2026206235A1
A mixing device for blending and measuring the thickness of fluids comprises a rotational motor with a motor shaft and a blade with a blade shaft. A torque sensor assembly connects the motor shaft to the blade shaft. The mixing motor operates in two modes. In mixing mode, the motor rotates in one direction at a high speed to mix and thicken fluids. In measuring mode, the motor rotates in the opposite direction at a low speed to assess the fluid's thickness. The rotation speed in this mode adapts to the thickness level of the fluid. A lift mechanism adjusts the height of a fluid container, allowing the blade to reach different depths for thorough mixing. Additionally, the device includes a powder container that dispenses a measured amount of thickening powder at the edge of the fluid container in a single release.
Resumen de: US20260298865A1
0000 A screen-printed sensor for detecting aluminum ions in food and biological samples is provided. The sensor includes an aluminum ion-selective membrane containing quercetin as an aluminum ionophore and multi-walled carbon nanotubes. The sensor provides a low-cost point of analysis method to determine aluminum ion concentration in a range of from 0.008 to 1070 μM in food and beverage materials, reflecting the general detection capability of the sensor under aqueous conditions.
Resumen de: WO2026199081A1
A multiplex biosensing device and system are disclosed, including a plurality of multiplex biosensing electrodes configured for simultaneous, real-time detection of multiple biomolecule markers. The multiplex biosensing electrodes may comprise working electrodes modified with diverse biosensing platforms. The biosensing platforms may include molecularly imprinted polymers, immunocomplex reactions, enzymatic reactions, or DNA hybridization, each customized to detect specific biomarkers. The device further includes a microfluidic delivery mechanism designed for the sequential processing and delivery of biofluid samples and reagents, using a separation or filter media to remove impurities. The multiplex biosensor system integrates the multiplex biosensing device and a detection apparatus may be wirelessly connected via Bluetooth or other communication modules, enabling remote, real-time data monitoring and analysis. The system supports various biofluids, including blood, plasma, urine, saliva, sputum, and sweat, facilitating diverse applications in health diagnostics, environmental monitoring, and food safety.
Resumen de: WO2026206998A1
Disclosed herein are methods and compositions for determining survival and treatment responsiveness of subjects with ovarian cancer. Specifically, the disclosure is directed to prognostic glucocorticoid receptor activity signatures for ovarian cancer. Also provided are methods for predicting responsiveness to certain cancer therapies (e.g., selective glucocorticoid receptor modulators (SGRMs)).
Resumen de: US20260298944A1
0000 Provided is a method for measuring a polypeptide aggregate in a sample, wherein the method comprises obtaining information regarding a concentration of the polypeptide aggregate in the sample using a calibrator, and the calibrator comprises a complex comprising: an oligopeptide comprising an epitope of the polypeptide aggregate; a hydrophilic polymer chain not comprising the epitope; and a carrier particle.
Resumen de: US20260298958A1
Disclosed is a specimen analysis method for analyzing a specimen regarding a plurality of measurement items, the specimen analysis method comprising: measuring a first measurement item and a second measurement item on the basis of a measurement order; executing a process related to a time difference between a measurement of the first measurement item and a measurement of the second measurement item; and obtaining a calculation value from a measurement value of the first measurement item and a measurement value of the second measurement item.
Resumen de: US20260298913A1
0000 The present disclosure relates to a method for detecting an analyte present in trace amounts in a fluid sample. The method includes at least: causing a fluid sample containing an analyte to flow over a substrate having an array of microchambers, with a first capture substance that specifically binds to the analyte immobilized in the microchambers; binding the analyte to the first capture substance; causing a second capture substance, which specifically binds to the analyte and binds to a signal-generating substance, to flow over the substrate; causing the signal-generating substance to flow over the substrate to bind to the second capture substance; causing a substrate solution to flow over the substrate; causing a hydrophobic solvent to flow over the substrate to remove the substrate solution present outside the microchambers; and counting and detecting the number of microchambers in which the fluorescence signal is generated.
Resumen de: US20260298946A1
The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.
Resumen de: US20260294329A1
0000 A non-invasive device for detecting Alzheimer's Disease-associated pathologies, comprising a fundus camera comprising a spectral reflectance imaging unit that includes a broadband light source and a light sensor and a lens assembly to focus light from the broadband light source onto a fundus of an eye, and one or more processors to detect reflected and/or backscattered light from the eye, illuminated by the broadband light source, using the light sensor for determining spectral reflectance information, generate a plurality of spectral reflectance maps comprising counts of reflected and/or backscattered light at a different wavelength or a different range of wavelengths, assign a weight to each of the spectral reflectance maps, and determine one or more regions of interest from the weighted spectral reflectance maps as being a potential Alzheimer's Disease-associated pathology based on a detection of one or more biomarkers indicative of Tauopathy.
Resumen de: AU2024347751A1
The present invention provides various biomarkers for identifying patients that are likely to benefit from treatment with a TLR inhibitor.
Resumen de: WO2025050066A1
The present disclosure provides compositions for activating TERT expression and methods of using the same for treating or ameliorating aging, aging-related diseases, and neurodegenerative conditions.
Resumen de: US20260297180A1
0000 The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating diseases and conditions associated with the priming and activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome. In particular embodiments, the method comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
Resumen de: US20260294328A1
0000 Disclosed herein are methods for diagnosing Alzheimer's disease in a subject that involves administering to the subject an imaging agent comprising hyperpolarized pyruvate having a nuclear magnetic resonance (NMR)-detectable nucleus; applying radiation to the brain of the subject, wherein the radiation has a frequency that excites electron spin transitions in the DNP agent at an intensity to polarize the NMR-detectable nucleus; detecting magnetic resonance signals in the brain of the subject from nuclear spin transitions in the NMR-detectable nucleus to produce a spectrum measuring bicarbonate (Bic) and lactate (Lac) metabolites; and calculating a Bic/Lac ratio from the measured metabolites, wherein a reduced Bic/Lac ratio compared to control is an indication that the subject has Alzheimer's disease.
Resumen de: US20260297486A1
0000 Disclosed herein are 3D culture systems and methods for producing epithelial tubular organoids, such as intestinal organoids. Also disclosed is a screening method that involves contacting elongated epithelial tubes produced from the disclosed systems and methods with a candidate agent, culturing the elongated epithelial tube in a growth medium under growth conditions, and evaluating the elongated epithelial tube for a physiological effect.
Resumen de: US20260298947A1
0000 A method for the in vitro diagnosis of a neurodegenerative disease, in a human or animal individual, at an early stage, including the step which includes in detecting the presence of at least one marker chosen from the derived forms of amyloid beta (Aβ) peptides selected from the oligomers of said peptides and the prefibrillar and fibrillar aggregated forms of said peptides, and the derived forms of phosphorylated tau proteins selected from the hyperphosphorylated forms of said proteins, the aggregated forms of said proteins and the modified phosphorylated tau proteins resulting from one or several post-translational modifications, the presence of the marker(s) being detected in a stool sample of said individual.
Resumen de: US20260298949A1
0000 Disclosed and claimed are compositions containing a calibrator and a stabilizer, wherein the stabilizer includes Diethylaminoethyl-(“DEAE”) dextran; D-Sorbitol, wherein the D-Sorbitol and DEAE-dextran are in a weight ratio from about 1:1 to about 5:2, a buffer; and a non-ionic surfactant; wherein the stabilizer is essentially free of bovine serum albumin; and wherein the calibrator is stabilized under frozen storage conditions, and remains stable when thawed and kept at temperatures of from about 2° C. to about 10° C. Also disclosed are methods of use of the claimed compositions and kits comprising the claimed compositions.
Resumen de: US20260298917A1
0000 This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.
Nº publicación: WO2026202211A1 01/10/2026
Solicitante:
NORDIC BIOSCIENCE AS [DK]
NORDIC BIOSCIENCE A/S
Resumen de: WO2026202211A1
Methods of immunoassay are described for detecting in a patient sample (such as for example a blood, serum or plasma sample) a biomarker originating from α-Synuclein, and to the use of said methods of immunoassay for detecting and/or monitoring Parkinson's Disease or a level of severity thereof. Monoclonal antibodies and assay kits for use in said methods of immunoassay are also described.
BOPI
Sede Electrónica
